Custom Synthesis/Nutraceuticals drive earnings growth
DIVI delivered in line 2QFY22 earnings led by strong offtake in the Custom Synthesis (CS) segment and ramp up in the Nutraceuticals segment. It has...
188 Views
DIVISLAB: DIVI delivered in line 4QFY21 earnings
DIVI delivered in line 4QFY21 earnings. It ended FY21 on a strong note, with 29%/57%/54% YoY growth in sales/EBITDA/PAT. New product development,...
290 Views
Divi's Labs: Peak Margins, Peak Valuation and Maturing Growth Profile - Juice Is No More
Divi's is a dominant global API manufacturer but is priced to perfection. With margins and valuations at peak and growth profile maturing, upside...
359 Views
Sensex Index Rebalance Preview: Take Profit on Strong Outperformance
With the review period for the Sensex almost complete, we still see DRRD as a high probability inclusion and ONGC as a deletion. With DRRD...
544 Views
Sensex Index Rebalance Preview: Early Look Sees One Change, Maybe Two
The S&P BSE Sensex is the flagship index of the Bombay Stock Exchange (BSE). The index has 30 stocks and is a free float weighted market cap...
861 Views